Home / Research Articles Hub / Inflammation and tumor progression: signaling path...
🧬 Medicine & Biology OpenAlex

Inflammation and tumor progression: signaling pathways and targeted intervention

📅 Published: July 12, 2021 👤 Huakan Zhao, Lei Wu, Guifang Yan et al. 📖 Signal Transduction and Targeted Therapy 📊 2,674 citations
AI-Generated Summary

Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Herein, we discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

Key Findings
  • 1 Chronic inflammation facilitates tumor progression and treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation of dendritic cells (DCs) and antigen presentation, leading to anti-tumor immune responses.
  • 2 In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers and activators of transcription (JAK-STAT), toll-like receptor (TLR) pathways, cGAS/STING, and mitogen-activated protein kinase (MAPK); inflammatory factors, including cytokines (e.g., interleukin (IL), interferon (IFN), and tumor necrosis factor (TNF)-α), chemokines (e.g., C-C motif chemokine ligands (CCLs) and C-X-C motif chemokine ligands (CXCLs)), growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β), and inflammasome; as well as inflammatory metabolites including prostaglandins, leukotrienes, thromboxane, and specialized proresolving mediators (SPM), have been identified as pivotal regulators of the initiation and resolution of inflammation.
  • 3 Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, and SPM have been developed to specifically modulate inflammation in cancer therapy, with some of these factors already undergoing clinical trials.
Why It Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source:

Read Full Paper at OpenAlex
More Medicine & Biology Papers ← Back to Hub 📚 Learning Hub